Sales of Hershey's Ice Breakers rose 8% in the first quarter, thanks to the trend.

While CEO Kirk Tanner didn't specify the connection, GLP-1 drug users have documented an unofficial side effect commonly ...

Hershey's gum and mint sales are rising as GLP-1 weight-loss drug users seek relief from side effects like 'Ozempic breath'.

Hershey says it's benefiting from the growing use of GLP-1 weight-loss drugs even as people cut down on snacks. Here's why.

So-called “Ozempic breath” is being linked to a boost in gum and mint sales, according to Hershey’s CEO. Medical ...

Q1 2026 Earnings Call April 29, 2026 8:00 PM EDTCompany ParticipantsAnoori Naughton - Vice President of Investor ...

Hershey's chief executive has credited the spread of Ozempic and other weight-loss drugs for an 8% jump in sales of the ...

This encourages bacteria that contribute to bad breath and the formation of cavities to thrive,” as Taylor explained it in an ...

Ozempic breath can be embarrassing for GLP-1 users — but it’s turned out to be good news for confectioners. Hershey Co. CEO ...

Q1 2026 Management View CEO Kirk Tanner framed the competitive backdrop as stable on pricing while acknowledging earlier-than-expected activity in the aisle, saying, "competition continues to be ...

Hershey beat first-quarter earnings estimates, driven partly by an 8% jump in Ice Breakers gum and mint sales linked to rising GLP-1 drug use. CEO Kirk Tanner highlighted 'functional snacking' as a ...

Kirk Tanner sees opportunities for the chocolate maker, as it navigates weight-loss drugs and stretched consumers.